Physician profile
Marvin E Ross
NPI 1346221231
$170.56
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $17.67 · 2021: $32.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.01 | 2019 | |
| Melinta Therapeutics, LLC | $22.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.34 | 2019 | |
| Abbvie INC. | $19.64 | 2021 | |
| Circassia INC. | $18.51 | 2019 | |
| Pfizer INC. | $17.67 | 2020 | |
| Amgen INC. | $14.76 | 2019 | |
| Novo Nordisk INC | $14.16 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.88 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.